UPPTHERA

Biotheryx

The company develops protein degrader medicines for patients with cancer and inflammatory diseases.

Amphista Therapeutics

This company develops targeted protein degradation medicines to treat patients with cancer and other diseases.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

ProtOS

This company develops artificial intelligence models to design de-novo proteins for the degradation of undruggable targets for the pharmaceutical and medical biotechnology industries.

Enodia

This company develops small-molecule therapies that degrade disease-causing proteins at the point of synthesis for patients with cancer and inflammatory diseases.

Plexium

This company develops targeted protein degradation therapeutics and discovery platforms for patients with cancer and neurodegenerative diseases.

Ligature Therapeutics

This biotech company develops protein degrader therapeutics using a fragment-based discovery platform to treat intractable diseases for patients with cancer.

UbiquiTx

This company develops a programmable protein modulation platform using artificial intelligence to create targeted therapies for pharmaceutical businesses and patients with complex diseases.